Tradestie Institutional Equity Comparison Engine

IONS vs INCY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INCY Overall Edge

INCY Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Incyte Genomics Inc (INCY) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus INCY at 14.0x Forward P/E and 32.2% operating margin (+14.0% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against INCY sits in CONSOLIDATION (64th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner INCY
IONS 90.9x vs INCY 14.0x Fwd P/E
Growth & Margin Winner INCY
Op Margin -58.8% vs 32.2% ยท YoY +54.9% vs +14.0%
Momentum & Technical Winner INCY
1Y -59.1% vs +13.7% ยท 52W Pos 2% vs 71%
Options & Structure Winner IONS
BREAKDOWN (17th %ile IV) vs CONSOLIDATION (64th %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
INCY NASDAQ
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$119.86
-0.92% 1D
Market Cap $24.8B
1M Return +6.01%
1Y Return +13.71%
Forward P/E 14.0x
Unified AI Score
61.2 / 100 BUY
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% INCY +13.71% Spread: +72.81 pp (INCY Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IONS Revenue INCY Revenue IONS Op. Margin INCY Op. Margin Margin Edge
FY2018 $600M $1.88B -10.2% 6.9% INCY
FY2019 $1.12B $2.16B 32.6% 18.6% IONS
FY2020 $730M $2.67B -23.6% -9.9% INCY
FY2021 $810M $2.99B -3.7% 19.6% INCY
FY2022 $590M $3.39B -69.8% 17.1% INCY
FY2023 $790M $3.70B -44.9% 16.8% INCY
FY2024 $710M $4.24B -67.4% 1.4% INCY
FY2025 $940M $5.14B -40.4% 29.5% INCY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (2) vs INCY (8)
Institutional Metric IONS INCY Criterion Row Winner
Market Capitalization Scale $4.7B $24.8B Larger Scale INCY
Trailing P/E Ratio Valuation 90.9x 62.1x Lower Multiple INCY
Forward P/E Ratio Valuation 90.9x 14.0x Lower Multiple INCY
Revenue Growth (YoY) Growth +54.9% +14.0% Higher Growth IONS
Operating Margin (TTM) Profitability -58.8% 32.2% Higher Margin INCY
Net Profit Margin Profitability -56.9% 6.7% Higher Margin INCY
Return on Equity (ROE) Capital Efficiency -108.0% 7.8% Higher ROE INCY
52-Week Range Position Momentum 2% ($27โ€“$87) 71% ($89โ€“$133) Stronger Trend INCY
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 0.30ฮฒ ยท 35% Vol Lower Realized Risk INCY
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 61.2 / 100 (BUY) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs INCY Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INCY CONSOLIDATION
78d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live INCY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor INCY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.